European biotech demonstrated its global relevance when BioNTech (Mainz) developed the world's first approved mRNA COVID vaccine in partnership with Pfizer. But the continent's biotech strength extends far beyond pandemic response: over 3,000 biotech companies operate across the EU, spanning therapeutic biotech (CureVac, Galapagos, Genmab), industrial biotech (Novozymes, Evonik Biotech), agricultural biotech (Biotalys, Agronutrition), and synthetic biology (Ginkgo Bioworks Europe, Basecamp Research).
In 2024, European biotech companies raised EUR 7.6 billion in venture capital and public offerings combined. The Innovative Health Initiative (IHI), successor to IMI2, channels EUR 2.4 billion in public-private funding toward drug discovery, diagnostics, and manufacturing innovation. Horizon Europe's Cluster 1 (Health) and Cluster 6 (Food, Bioeconomy) together allocate over EUR 17 billion to bio-related research, making the EU the world's most generous public funder of life-science R&D.
For biotech founders, Europe offers unmatched clinical trial infrastructure (harmonised under the Clinical Trials Regulation), world-class research hospitals, and an EMA centralised marketing authorisation that provides access to 450 million patients in a single regulatory filing. The challenge is Series B and beyond, where US biotech investors and NASDAQ listings historically absorbed European innovation — a dynamic that BioNTech's Frankfurt listing and Galapagos' Euronext success are beginning to reverse.
EU Funding Landscape for Biotech
The EU pharmaceutical market is the world's second-largest (EUR 290B annually). Europe hosts 10 of the world's top 20 pharmaceutical companies and produces 40 % of global biopharmaceutical patents. The BioRegions network connects 14 life-science clusters, from the Medicon Valley (Copenhagen-Malmo) to BioValley (Basel-Strasbourg-Freiburg), creating the world's densest network of biotech talent and infrastructure.
EU Funding for Biotech
EIC Accelerator Up to €17.5M
Biotech is the EIC's top-funded sector by volume. Phase II clinical-stage companies, platform technology developers, and industrial biotech scale-ups routinely receive the full EUR 17.5M blended finance.
EIC Pathfinder Up to €4M
Funds breakthrough biotech research: synthetic biology, gene therapy vectors, organ-on-chip, and AI-driven protein engineering at TRL 1-4.
EIC Transition Up to €2.5M
Bridges lab-stage biotech research toward IND-enabling studies, GMP manufacturing setup, and regulatory pre-submission meetings.
Horizon Cluster 4 €2M–5M per project
Cluster 1 (Health) funds translational research, clinical trials, and health technology assessment studies. Cluster 6 covers industrial and agricultural biotech.
AI TEFs Varies by TEF (services and access, not direct grants)
The Healthcare AI TEF provides real-world testing for AI-driven diagnostics, drug discovery tools, and clinical decision support systems in regulated healthcare environments.
Top European Hubs for Biotech
Basel, Switzerland
Roche and Novartis HQs anchor the BioValley tri-national cluster (CH/FR/DE); 700+ life-science companies, the world's highest density of pharma R&D spending per capita.
Copenhagen, Denmark
Medicon Valley: Novo Nordisk, Lundbeck, Genmab, and 350+ biotech companies across the Oresund bridge, supported by EUR 3B annual life-science R&D spending.
Cambridge, United Kingdom
AstraZeneca HQ, MRC Laboratory of Molecular Biology, and 500+ biotech companies make this Europe's densest life-science cluster outside Basel.
Munich, Germany
BioNTech R&D labs, MorphoSys, and Helmholtz Munich. The Bavarian biotech cluster has attracted EUR 2B+ in VC since 2020.
Leiden, Netherlands
Galapagos, Pharming, and ProQR anchor the Leiden Bio Science Park — Europe's largest single-site biotech cluster with 180+ companies.
EU Regulations Affecting Biotech
Clinical Trials Regulation (536/2014)
Harmonised EU-wide clinical trial authorisation through the CTIS portal. Multi-country trial applications can be submitted simultaneously, reducing approval timelines from 12+ months to 60 days for the initial assessment.
EMA Centralised Procedure
A single marketing authorisation application to EMA grants market access across all 27 EU member states plus EEA countries — covering 450 million patients in one regulatory filing.
ATMP Regulation (1394/2007)
Specific regulatory pathway for Advanced Therapy Medicinal Products (gene therapies, cell therapies, tissue-engineered products) with dedicated EMA committee (CAT) assessment.
EU Bioeconomy Strategy
EUR 100B mobilised toward sustainable bio-based industries. Drives funding and procurement preferences for industrial biotech solutions replacing fossil-based chemicals and materials.
Biotech Startups in Europe
ACTOME
First time ultra-sensitive and simultaneous quantification of proteins, interactions
Germany
ALLERO THERAPEUTICS
Novel First-in-Class Specific Oromucosal Immunotherapy (SOMIT) to treat Celiac Disease (CD)
Netherlands
APMONIA THERAPEUTICS
Breaking boundaries in cancer by targeting its microenvironment
France
ARTHEX BIOTECH
First In class oliGo THerapy for Myotonic Dystrophy type 1 (DM1)
Spain
AVIWELL
Animal Microbiome Discovery Platform
France
CELLBOX SOLUTIONS
Innovative logistic solutions for the global BioMed industry
Germany
CELTIC BIOTECH
Development of a natural therapeutic treatment for late-stage lung cancer patients
Ireland
CHAINCRAFT
The development of a full scale plant for the production of sustainable medium chain fatty acids
Netherlands
CHERRY BIOTECH
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
France
Genewity Holding
The i-Thymus: wielding the potential of gene therapy
Netherlands
INOBIOSTAR
INNOAEROGEL: SUSTAINABLE SORBENT FOR AQUATIC OIL SPILLS CLEAN UP
Lithuania
INSPEK
An innovative on-chip multi-sensing platform for single-use biopharmaceutical applications
France
INTEGRA THERAPEUTICS
Next generation gene writing platform to cure genetic and oncological diseases
Spain
INVERA MEDICAL LIMITED
Innovative catheter system for less invasive infusion
Ireland
JAXBIO TECHNOLOGIES
INNOVATIVE LIQUID BIOPSY METHOD USING LAB-ON-ACHIP TECHNOLOGY FOR CANCER DIAGNOSIS AND MANAGEMENT
Israel
KERN TEC
Unlocking fruit seeds for food and cosmetics
Austria
MELT&MARBLE
Rethinking fats and lipids for food and personal care
Sweden
NC BIOMATRIX
Injectable biomaterial gel for spinal disc degeneration treatment
Netherlands
NECTIN THERAPEUTICS
Next-generation immune-oncology biotechnology for cancer treatment
Israel
NOVOBIOM
A fungi-based biotechnological platform for competitive multi-stream waste revalorization.
Belgium
ONEGO BIO
Novel precision fermentation process to produce animal-free bioidentical ovalbumin
Finland
PALO BIOFARMA
Biopharmaceutical company focused on adenosine signaling
Spain
PharmNovo
PN6047 - a breakthrough treatment of neuropathic pain
Sweden
SCIPIO BIOSCIENCE
Innovative single-cell RNA-seq kit to support large democratization of insgle-cell analysis
France
SMART IMMUNE
A New Lymphoid Technology That Accelerates Immune
France
SOLMEGIA MONOPROSOPI I.K.E.
Inspiring CO2 circularity by introducing carbon transformation to our plates
Greece
TILT BIOTHERAPEUTICS
Fighting cancer with next generation oncolytic immunotherapy in ovarian, head & neck
Finland
TOOPI ORGANICS
Plant biostimulants derived from fermented human urine
France
VAXDYN
Vaccine development company focused on preventing life-threatening infections
Spain
VBL Therapeutics
The OVAL study for VB-111 treatment of platinum-resistant ovarian cancer
Israel
VCs Investing in Biotech
Atomico
London, UK 🇬🇧
Balderton Capital
London, UK 🇬🇧
Lakestar
Zürich, Switzerland 🇨🇭
EQT Ventures
Stockholm, Sweden 🇸🇪
Northzone
Stockholm, Sweden 🇸🇪
Speedinvest
Vienna, Austria 🇦🇹
Partech
Paris, France 🇫🇷
Alven
Paris, France 🇫🇷
Frequently Asked Questions
EMA's centralised procedure covers 27+3 countries in one filing, but typically takes 210 days (vs. FDA's 180-day target). EMA requires more comparative effectiveness data and health technology assessment considerations. However, EMA's PRIME (Priority Medicines) designation accelerates promising therapies with enhanced dialogue, similar to FDA Breakthrough Therapy.
IHI is a EUR 2.4B public-private partnership replacing IMI2. It funds collaborative projects between industry, academia, and SMEs in drug discovery, diagnostics, and digital health. Biotech startups can join consortia responding to IHI calls, typically receiving EUR 0.5-2M per project for 3-5 years. Unlike EIC, IHI does not take equity.
Yes. The Clinical Trials Regulation (fully operational since January 2023) enables multinational trial applications through the CTIS portal. A single submission is assessed by a reporting member state with coordinated review by participating countries. Approval timelines are 60 days for initial assessment, making multi-country EU trials more efficient than running separate national approvals.
Yes. CRISPR and gene-editing therapeutics are explicitly funded under Horizon Europe Cluster 1 and EIC Pathfinder. European companies like CRISPR Therapeutics (originally Basel-based), Basecamp Research, and Mammoth Biosciences Europe work on gene-editing applications. The EU's regulatory framework for ATMPs provides a clear (if demanding) path to market for gene therapies.
Explore Other Sectors
Get EU Funding for Your Biotech Startup
EUACC matches biotech startups with the right EU programmes and helps you write winning applications with AI trained on funded proposals.
Start Your Application